甲状旁腺切除术与继发性甲状旁腺功能亢进患者较低死亡率和较少心脏并发症相关
本研究基于TriNetX电子健康记录(2004-2025)回顾性分析肾源性继发性甲状旁腺功能亢进患者,比较甲状旁腺切除术与西那卡塞治疗的长期结局。倾向评分匹配后,甲状旁腺切除术与较低的全因死亡风险(HR 0.68, 95%CI 0.58-0.80)和复合心脏事件风险(HR 0.75, 95%CI 0.64-0.87)相关,在甲状旁腺激素≤585 pg/mL患者中仍一致。
要点
- 甲状旁腺切除术与较低死亡风险相关(HR 0.68, 95%CI 0.58-0.80)。
- 甲状旁腺切除术与较低复合心脏事件风险相关(HR 0.75, 95%CI 0.64-0.87)。
- 甲状旁腺激素≤585 pg/mL患者中,手术仍与较低死亡和心脏风险相关。
核心结论
- 甲状旁腺切除术可能较西那卡塞提供更优的长期生存和心血管结局,即使在甲状旁腺激素中度升高的患者中。
研究设计与样本
- 回顾性分析使用TriNetX平台电子健康记录(2004-2025),纳入肾源性继发性甲状旁腺功能亢进且有维生素D或磷结合剂用药史的患者。
- 共11,581例患者,1,478例(12.8%)接受甲状旁腺切除术,10,103例(87.2%)接受西那卡塞;倾向评分匹配(1:1)后每组1,227例。
- 采用Cox比例风险模型估计死亡和心脏结局的风险比及95%置信区间。
主要发现
- 中位随访4年,甲状旁腺切除术与较低死亡风险相关(HR 0.68, 95%CI 0.58-0.80)。
- 甲状旁腺切除术与较低复合心脏事件风险相关(HR 0.75, 95%CI 0.64-0.87)。
- 甲状旁腺切除术还与较低缺血性心脏病、心力衰竭和心律失常风险相关。
- 甲状旁腺激素≤585 pg/mL患者中,甲状旁腺切除术仍与较低死亡风险(HR 0.73, 95%CI 0.59-0.90)和心脏风险(HR 0.62, 95%CI 0.50-0.77)相关。
临床怎么用
- 对于肾源性继发性甲状旁腺功能亢进患者,在传统治疗基础上,甲状旁腺切除术可能作为西那卡塞的替代选择以改善长期生存和心血管结局。
- 即使甲状旁腺激素水平仅中度升高(≤585 pg/mL),甲状旁腺切除术仍可能带来生存和心脏获益。
局限性
- 本研究为回顾性分析,可能存在未测量的混杂因素。
- 研究基于电子健康记录数据,可能存在数据完整性和准确性的局限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Secondary hyperparathyroidism can be treated with calcimimetics such as cinacalcet or surgically with parathyroidectomy. The adoption of cinacalcet has reduced the frequency of surgical management. This study evaluates the long-term outcomes of parathyroidectomy versus cinacalcet in patients with renal-origin secondary hyperparathyroidism who previously received conventional therapy. METHODS: We conducted a retrospective analysis using electronic health records (2004-2025) from the TriNetX platform. Patients with renal-origin secondary hyperparathyroidism and a medication history of vitamin D or phosphate binders were included. Those treated with cinacalcet for ≥6 months were compared to those who underwent parathyroidectomy without cinacalcet use or kidney transplantation. Propensity score matching (1:1) controlled for demographics, comorbidities, and cardiovascular therapies. Cox proportional hazards models estimated hazard ratios and 95% confidence intervals for mortality and cardiac outcomes. RESULTS: Among 11,581 patients, 1,478 (12.8%) underwent parathyroidectomy and 10,103 (87.2%) received cinacalcet. After matching, 1,227 patients were included in each group. Over a median follow-up of 4 years, parathyroidectomy was associated with lower risks of mortality (hazard ratio 0.68, 95% confidence interval 0.58-0.80) and composite cardiac events (0.75, 0.64-0.87). It was also associated with lower risks of ischemic heart disease, heart failure, and arrhythmias. Among patients with parathyroid hormone ≤585 pg/mL, parathyroidectomy remained associated with lower mortality (hazard ratio 0.73, 95% confidence interval 0.59-0.90) and cardiac risk (0.62, 0.50-0.77). CONCLUSIONS: Parathyroidectomy may provide superior long-term survival and cardiovascular outcomes compared to cinacalcet, even in patients with moderately elevated parathyroid hormone.
引用
- Song Z, Kasmirski J, Balachandra S, et al. Parathyroidectomy is associated with lower mortality and fewer cardiac complications in patients with secondary hyperparathyroidism. Surgery. 2025. PMID: 41238436. doi:10.1016/j.surg.2025.109851
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。